95 related articles for article (PubMed ID: 10547570)
21. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
22. Expression of Bcl-2 and p53 correlates with the morphology of gastric neoplasia.
Kyokane K; Ito M; Sato Y; Ina K; Ando T; Kusugami K
J Pathol; 1998 Apr; 184(4):382-9. PubMed ID: 9664903
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of p53/bcl-2 co-expression in patients with laryngeal squamous cell carcinoma.
Jäckel MC; Sellmann L; Dorudian MA; Youssef S; Füzesi L
Laryngoscope; 2000 Aug; 110(8):1339-45. PubMed ID: 10942137
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis-related proteins.
Kawauchi S; Fukuda T; Oda Y; Saito T; Oga A; Takeshita M; Yokoyama K; Chuman H; Iwamoto Y; Sasaki K; Tsuneyoshi M
Mod Pathol; 2000 Jul; 13(7):755-65. PubMed ID: 10912935
[TBL] [Abstract][Full Text] [Related]
26. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
Lee WY; Jin YT; Tzeng CC
Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
[TBL] [Abstract][Full Text] [Related]
27. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma.
Kaseta MK; Khaldi L; Gomatos IP; Tzagarakis GP; Alevizos L; Leandros E; Papagelopoulos PJ; Soucacos PN
J Surg Oncol; 2008 Mar; 97(3):259-66. PubMed ID: 18161867
[TBL] [Abstract][Full Text] [Related]
29. Significantly different bcl-2 expression profiles in gastric and non-gastric primary extranodal high-grade B-cell lymphomas.
Cogliatti SB; Griesser H; Peng H; Du MQ; Isaacson PG; Zimmermann DR; Maibach RC; Schmid U
J Pathol; 2000 Dec; 192(4):470-8. PubMed ID: 11113864
[TBL] [Abstract][Full Text] [Related]
30. Microsatellite analysis of breast carcinoma and corresponding local recurrences.
Regitnig P; Moser R; Thalhammer M; Luschin-Ebengreuth G; Ploner F; Papadi H; Tsybrovskyy O; Lax SF
J Pathol; 2002 Oct; 198(2):190-7. PubMed ID: 12237878
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
Hagel C; Krog B; Laas R; Stavrou DK
J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
[TBL] [Abstract][Full Text] [Related]
32. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
[TBL] [Abstract][Full Text] [Related]
33. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
34. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.
Swellam M; Ismail M; Eissa S; Hamdy M; Mokhtar N
IUBMB Life; 2004 Aug; 56(8):483-90. PubMed ID: 15545228
[TBL] [Abstract][Full Text] [Related]
35. Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours.
Karim RZ; Gerega SK; Yang YH; Horvath L; Spillane A; Carmalt H; Scolyer RA; Lee CS
J Clin Pathol; 2009 Nov; 62(11):1016-20. PubMed ID: 19861560
[TBL] [Abstract][Full Text] [Related]
36. Relationship of p53, Bcl-2, Ki-67 index and E-cadherin expression in early invasive breast cancers with comedonecrosis as an accelerated apoptosis.
Hosaka N; Ryu T; Cui W; Li Q; Nishida A; Miyake T; Takaki T; Inaba M; Ikehara S
J Clin Pathol; 2006 Jul; 59(7):692-8. PubMed ID: 16473926
[TBL] [Abstract][Full Text] [Related]
37. Phyllodes tumour of the breast: immunohistochemical study of 37 tumours using MIB1 antibody.
Kocová L; Skálová A; Fakan F; Rousarová M
Pathol Res Pract; 1998; 194(2):97-104. PubMed ID: 9584322
[TBL] [Abstract][Full Text] [Related]
38. P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up.
Carlinfante G; Lazzaretti M; Ferrari S; Bianchi B; Crafa P
Pathol Res Pract; 2005; 200(11-12):791-9. PubMed ID: 15792122
[TBL] [Abstract][Full Text] [Related]
39. p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome.
Feakins RM; Mulcahy HE; Nickols CD; Wells CA
Histopathology; 1999 Aug; 35(2):162-9. PubMed ID: 10460662
[TBL] [Abstract][Full Text] [Related]
40. Predictors of phyllodes tumours on core biopsy specimens of fibroepithelial neoplasms.
Jara-Lazaro AR; Akhilesh M; Thike AA; Lui PC; Tse GM; Tan PH
Histopathology; 2010 Aug; 57(2):220-32. PubMed ID: 20716164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
